CIPFOSIN/ CIPLA FOSFOMYCIN (Cipla Australia Pty Ltd)
CIPFOSIN/ CIPLA FOSFOMYCIN is indicated only for the treatment of acute uncomplicated lower urinary tract infections (acute cystitis) in females above 12 years of age caused by the following susceptible pathogens: Escherichia coli, or Enterococcus faecalis.
CIPFOSIN/ CIPLA FOSFOMYCIN is not indicated for the treatment of pyelonephritis or perinephric abscess or where resistance is likely (previous treatment failure, infection due to non-susceptible organism).
Appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to CIPFOSIN/ CIPLA FOSFOMYCIN. However, therapy may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. Consideration should be given to the relevant clinical guidelines on the appropriate use of antibacterial agents.